On 16 April 2018, orphan designation (EU/3/18/2012) was granted by the European Commission to IDEA Innovative Drug European Associates Limited, United Kingdom, for genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (also known as KB103) for treatment of epidermolysis bullosa.
genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII
|Disease / condition||
Treatment of epidermolysis bullosa
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.